ライフサイエンスコーパス: lymph node metastasis

1 extension (two of these developed a regional lymph node metastasis).

2 ntly associated with histological grades and lymph node metastasis.

3 fied tumor cells from human breast tumor and lymph node metastasis.

4 ariation in a primary acral melanoma and its lymph node metastasis.

5 n the stromal fibroblasts is associated with lymph node metastasis.

6 PAK1 protein expression was associated with lymph node metastasis.

7 sion in lymphatic endothelial cells, LVI, or lymph node metastasis.

8 remains the modality of choice for detecting lymph node metastasis.

9 s on multiple tumors, vascular invasion, and lymph node metastasis.

10 omy was performed for patients with sentinel lymph node metastasis.

11 showed independent influence on the rate of lymph node metastasis.

12 nd showed increased local tumor invasion and lymph node metastasis.

13 cer depends especially on the probability of lymph node metastasis.

14 sed patients at the lowest risk of harboring lymph node metastasis.

15 tion, Grading G1 or <1 cm in diameter had no lymph node metastasis.

16 or, AdTSTA-sr39tk, to target prostate cancer lymph node metastasis.

17 C in prostate cancer is also correlated with lymph node metastasis.

18 plays a marked predilection for locoregional lymph node metastasis.

19 ) correlates with an increased likelihood of lymph node metastasis.

20 me 8p21.1-p21.2 as a sole deletion developed lymph node metastasis.

21 prostate cancer seminal vesicle invasion and lymph node metastasis.

22 of patients, particularly in the absence of lymph node metastasis.

23 ors show a predilection for lung rather than lymph node metastasis.

24 ormal thyroid tissue, primary PTC, and a PTC lymph node metastasis.

25 CXCL13, or RANKL was sufficient to decrease lymph node metastasis.

26 of cancer cells can reveal critical steps of lymph node metastasis.

27 and BRAF mutation as prognostic factors for lymph node metastasis.

28 The combination therapy completely inhibited lymph node metastasis.

29 ival time and an increase in tumor stage and lymph node metastasis.

30 associated with tumor lymphangiogenesis and lymph node metastasis.

31 tumors (P < 0.01) and complete inhibition of lymph node metastasis.

32 e and weight, and a decrease in incidence of lymph node metastasis.

33 al lymphangiogenesis but are unnecessary for lymph node metastasis.

34 umor mass and a decrease in the incidence of lymph node metastasis.

35 ethylation may increase the risk of regional lymph node metastasis.

36 ese marginal vessels could be sufficient for lymph node metastasis.

37 ervation of bone structure, and reduction of lymph node metastasis.

38 assessable patients, 648 had no evidence of lymph node metastasis.

39 ated in HNCs, especially in the tissues with lymph node metastasis.

40 ndothelial cells) and inhibition of regional lymph node metastasis.

41 s validated in a rat breast tumor model with lymph node metastasis.

42 e of heterogeneity between primary tumor and lymph node metastasis.

43 xpression was associated with the absence of lymph node metastasis.

44 icroscopic nonpalpable and palpable regional lymph node metastasis.

45 ng ductal carcinomas; and one (2%), axillary lymph node metastasis.

46 vasion microscopically, and 58% had regional lymph node metastasis.

47 tumor subclones, or subclones in an axillary lymph node metastasis.

48 mph node metastasis, whereas 471 (58.6%) had lymph node metastasis.

49 titute it for SLNB for exclusion of axillary lymph node metastasis.

50 -expression diminishes lymphangiogenesis and lymph node metastasis.

51 merican Joint Committee on Cancer) stage III lymph node metastasis.

52 a very early stage of tumour development and lymph node metastasis.

53 tiated thyroid cancer of 1 cm or more and/or lymph node metastasis.

54 entral tumour, the tumour invasive front and lymph node metastasis.

55 ced stages of breast cancer, as well as with lymph node metastasis.

56 8.0 vs 19.0 months; P = 0.239) regardless of lymph node metastasis.

57 absence or presence of pathologically proven lymph node metastasis.

58 t impact liver metastasis despite abrogating lymph node metastasis.

59 +) metastatic tumor cells, thereby promoting lymph node metastasis.

60 nvasive ability and incidence of spontaneous lymph node metastasis.

61 HL2 expression in primary breast cancers and lymph node metastasis.

62 th propeptides is required for high rates of lymph node metastasis.

63 tively correlated with tumor stage, size and lymph node metastasis.

64 knockdown with shRNA significantly decreased lymph node metastasis.

65 ic approach for the prevention and arrest of lymph node metastasis.

66 or IFP and interstitial hypertension-induced lymph node metastasis.

67 ration but no apoptosis, presenting frequent lymph-node metastasis.

68 but (68)Ga-PSMA-11 PET/CT showed additional lymph nodes metastasis.

69 esence of multiple tumors (1.70; 1.43-2.02), lymph node metastasis (2.09; 1.80-2.43), vascular invasi

70 Approximately one-third of the patients had lymph node metastasis (34%) or vascular (38%), perineura

71 capsular invasion (29% v 16%; P = .045), and lymph node metastasis (38% v 18%; P = .002).

72 frequent extrathyroidal extension (51%) and lymph node metastasis (46%).

73 frequent extrathyroidal extension (4.6%) and lymph node metastasis (5.6%).

74 prostate invasion (46% weight reduction) and lymph node metastasis (50% inhibition).

75 T2-T4, 96% vs. 73%, P < 0.001); (2) regional lymph node metastasis (78% vs. 51%, P < 0.001); (3) poor

76 (83%), localized prostate cancer (100%), and lymph node metastasis (80%), but decreased to 40% in met

77 this study was to evaluate the frequency of lymph node metastasis according to the depth of tumor in

78 ted HR, 0.74; 95% CI, 0.62 to 0.88), time to lymph node metastasis (adjusted HR, 0.70; 95% CI, 0.51 t

79 lore the contributions of c-Met signaling to lymph node metastasis after inhibition of VEGF signaling

80 udy was to determine factors associated with lymph node metastasis among hormonally-responsive breast

81 identified 33 patients (32%) with a sentinel lymph node metastasis and 70 patients (68%) with tumor-f

82 mas (HNSCC) and breast cancer, which display lymph node metastasis and an unfavorable clinical outcom

83 ressed in NPC and positively correlated with lymph node metastasis and clinical stage of NPC.

84 s a significant risk factor for locoregional lymph node metastasis and has potential utility as a sur

85 ed in invasive carcinomas of the breast with lymph node metastasis and in inflammatory breast cancer.

86 Lymph node metastasis and local invasion of head and nec

87 e positively correlated with invasion depth, lymph node metastasis and negatively correlated with the

88 including one for whom we sequenced CTCs, a lymph node metastasis and nine cores of the primary tumo

89 encoding cIAP1 and cIAP2, is associated with lymph node metastasis and poor clinical outcome in OSCC.

90 breast cancers and has been correlated with lymph node metastasis and poor prognosis in breast cance

91 An association between lymph node metastasis and poor prognosis in breast cance

92 CLIC3 expression predicts lymph node metastasis and poor prognosis in operable cas

93 ion level and is associated with late-stage, lymph node metastasis and poor prognosis, as well as tri

94 that GIRK1 may be useful as a biomarker for lymph node metastasis and possibly a pharmaceutical targ

95 The established relationship between lymph node metastasis and prognosis in colorectal cancer

96 To ascertain the roles of cIAP1/cIAP2 in lymph node metastasis and radioresistance, we use an in

97 a highly invasive phenotype associated with lymph node metastasis and reduced survival.

98 ination treatment also led to a reduction in lymph node metastasis and reductions in both the frequen

99 consistent with a role of lymphatic drain in lymph node metastasis and suggest that increased lymph n

100 r, because some of these are associated with lymph node metastasis and survival and might be useful a

101 roups, younger ages showed increased risk of lymph node metastasis and thicker tumors.

102 ethylation was significantly associated with lymph node metastasis and this relationship was dependen

103 hangiogenesis may be related to the risk for lymph node metastasis and to patient survival, using dou

104 pression was associated with the presence of lymph node metastasis and tumor stage III-IV.

105 e advanced disease (greatest tumor diameter, lymph node metastasis) and decreased serum albumin conce

106 ival and (1) T category at presentation, (2) lymph node metastasis, and (3) distant metastasis.

107 estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression.

108 de mice, the primary tumor volumes, axillary lymph node metastasis, and lung metastasis were signific

109 sion was inversely correlated with invasion, lymph node metastasis, and poor clinical outcomes.

110 esiologists class, body mass index, count of lymph node metastasis, and specimen length.

111 included large tumor size, multiple tumors, lymph node metastasis, and vascular invasion.

112 cal covariates, including depth of invasion, lymph-node metastasis, and stage.

113 asis (CRLM), intrahepatic lymph invasion and lymph node metastasis are poor prognostic factors.

114 Depth of invasion and the extent of lymph node metastasis are the most important predictors

115 Extensive local invasion and regional lymph node metastasis are, in large part, responsible fo

116 ncing complex PRC2/EED-EZH2 in breast cancer lymph node metastasis as compared to primary tumor and i

117 the invasive component of primary tumor and lymph node metastasis at multiple target sites followed

118 a was significantly associated with regional lymph node metastasis: ATA42G12 (chromosome 1, P = .0009

119 98, with histologic confirmation of regional lymph node metastasis before clinical evidence of distan

120 cted to the diagnosis of hepatic lesions and lymph node metastasis but functionalization of these mat

121 mor stages, HER2 expression status, and high lymph node metastasis but inversely correlated with rela

122 Cells derived from a lymph node metastasis, but not from a synchronous primar

123 on analysis identified 31 genes expressed in lymph node metastasis, but not in the primary tumor.

124 AFP), tumor-node-metastasis (TNM) stage, and lymph node metastasis, but not with other clinicopatholo

125 clear-cell carcinoma from a supraclavicular lymph node metastasis by analysis of G-banded metaphase

126 Prevention of lymph node metastasis by PF-04217903 in this setting imp

127 tem that omits information on tumor size and lymph node metastasis (c = 0.67).

128 mors in RIP-Tag2 transgenic mice and whether lymph node metastasis can be reduced by concurrent inhib

129 Patients with regional lymph node metastasis can enjoy significant long-term su

130 e primary tumors, only 12 (17%) patients had lymph node metastasis (chi, P < 0.0001).

131 (4%) with tumors < or = 1.0 cm had regional lymph node metastasis, compared with 51 (24%) of 213 pat

132 induced progesterone receptors, and promoted lymph node metastasis, confirming that ERs are functiona

133 regional lymph nodes, and the appearance of lymph node metastasis correlates with poor prognosis.

134 We concluded that lymph node metastasis could be predicted by gene express

135 Lymph node metastasis demonstrated lower values compared

136 by intrinsic biological differences such as lymph node metastasis, distant metastasis, and triple-ne

137 determined that concurrent liver metastasis, lymph node metastasis, Eastern Cooperative Oncology Grou

138 elanoma tumor cell sublines established from lymph node metastasis express higher amounts of VEGF-C t

139 When lymph node metastasis, extrathyroidal invasion, and dist

140 ncreases in positive posttest probability of lymph node metastasis for all methods.

141 Although the presence of lymph node metastasis form HCC has been considered as a

142 inical setting, decreased the probability of lymph node metastasis from 15% to 44% (pretest) to 3% to

143 of 15 lung adenocarcinomas and one regional lymph node metastasis from 6 patients with MSLC.

144 maging perform similarly in the detection of lymph node metastasis from cervical cancer.

145 otherapy, and two tumours were paired with a lymph node metastasis from the same patient.

146 with melanoma, and the presence of regional lymph node metastasis has been commonly used as an indic

147 based on its lower rate of advanced T stage, lymph node metastasis, high tumor grade, positive resect

148 iting this pathway potently blocked lung and lymph node metastasis; however, primary tumors and estab

149 8; P < .001), cirrhosis (HR, 1.51; P = .08), lymph node metastasis (HR, 1.78; P = .01), and macrovasc

150 subsequently underwent SLNB, which revealed lymph node metastasis in 12 (27%) patients.

151 +) CSCs mediate invasive growth and cervical lymph node metastasis in a mouse model of HNSCC.

152 ological quantification revealed spontaneous lymph node metastasis in all Hyal1 transfectant-implante

153 However, pure genistein showed increased lymph node metastasis in an animal model, but such an ad

154 riables have been described as predictors of lymph node metastasis in breast cancer.

155 bilities for the treatment and prevention of lymph node metastasis in breast cancer.

156 a novel prognostic indicator for the risk of lymph node metastasis in cutaneous melanoma.

157 G1 overexpression promotes cell motility and lymph node metastasis in ESCC patients, leading to poore

158 r alteration correlated with the presence of lymph node metastasis in head and neck cancer.

159 axis due to miR-376c downregulation fosters lymph node metastasis in HNSCC.

160 spread in a mouse model and correlates with lymph node metastasis in human patients with pancreatic

161 d with larger tumors, higher TNM stages, and lymph node metastasis in NSCLC patients.

162 Current assessment of lymph node metastasis in patients with head and neck squ

163 Inhibition of VEGF signaling can promote lymph node metastasis in preclinical models, but the mec

164 to delineation of local recurrence or pelvic lymph node metastasis in selected patients; the lower he

165 nical prediction rule to predict the risk of lymph node metastasis in this population.

166 egulation of ATF3 expression correlated with lymph node metastasis in TP53-mutated human lung cancer.

167 Multifocality did not affect lymph node metastasis in tumors <=1 cm.

168 r cell adhesion to lymphatic endothelium and lymph node metastasis in vivo, whereas genetic or pharma

169 clones demonstrated reduction of spontaneous lymph node metastasis incidence (13%), spontaneous lymph

170 gical castration further reduced spontaneous lymph node metastasis incidence and volume (18% and 28%,

171 The frequency of lymph node metastasis increased with clinical stage and

172 presence of a gene expression signature for lymph node metastasis indicates that clinical testing to

173 Regional lymph node metastasis is a common event in solid tumors

174 ted lung cancer, the presence of mediastinal lymph node metastasis is a critical determinant of thera

175 Lymph node metastasis is a key event in the progression

176 mphatic vessels to regional lymph nodes, and lymph node metastasis is a major determinant for the sta

177 Regional lymph node metastasis is a major determinant of outcome

178 Lymph node metastasis is a multifactorial event.

179 The extent of lymph node metastasis is a prognostic indicator of disea

180 Lymph node metastasis is an important prognostic factor

181 ction can be realistically obtained and when lymph node metastasis is not evident.

182 treatment is initiated before metastasis to lymph nodes, metastasis is prevented.

183 Lymph-node metastasis is an indicator of poor prognosis

184 using on pathological diagnosis, size, local lymph node metastasis (LNM) of the tumors.

185 mportant route for cancer dissemination, and lymph node metastasis (LNM) serves as a critical prognos

186 with stage III cutaneous melanoma (excluding lymph node metastasis </=1 mm or in-transit metastasis)

187 with stage III cutaneous melanoma (excluding lymph node metastasis </=1 mm or in-transit metastasis)

188 breast cancer patients at low likelihood of lymph node metastasis may be spared lymph node evaluatio

189 h node metastasis and suggest that increased lymph node metastasis may occur due to a combination of

190 as performed in a mouse B16F10 melanoma limb lymph node metastasis model (n = 13) to survey the devel

191 atched cases of primary melanomas with early lymph node metastasis (n = 18) and from nonmetastatic me

192 ially in early clinical stage, low grade and lymph node metastasis-negative breast carcinoma.

193 istinct from these classic subtypes, such as lymph node metastasis, new melanomas, and genital and or

194 It is also possible that lymph node metastasis occurred via the cancer cell-beari

195 remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95% confidence

196 emination to the lymph nodes and macroscopic lymph node metastasis of B16F10 melanoma.

197 ssion of P-Rex1, but not its mutant, induced lymph node metastasis of CWR22Rv1 cells without an effec

198 ith tumor differentiation but inversely with lymph node metastasis of esophageal SCC.

199 1), and associated with stage (P=0.0001) and lymph node metastasis of NSCLC (P=0.0019).

200 UMSCC22B) derived from the primary tumor and lymph node metastasis of the same patient.

201 mutation [OR (95% CI) = 4.2 (1.2-14.6)] and lymph node metastasis [OR (95% CI) = 7.75 (2.1-28.5)] we

202 nd that GIRK1 overexpression correlated with lymph node metastasis (P < 0.0029), and overexpression w

203 5, 18, 20, and 22 in the stroma and regional lymph node metastasis (P = .0002-.0016), and on chromoso

204 therapy before or during SRT (P < .001), and lymph node metastasis (P = .019).

205 high Gleason grade (P < 0.0001), presence of lymph node metastasis (P = 0.0002), hormone-refractory d

206 on, and seminal vesicle invasion, as well as lymph node metastasis (P = 0.0021).

207 esentation was significantly associated with lymph node metastasis (P = 0.0079).

208 t of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the invol

209 ndependently associated with the presence of lymph node metastasis (P = 0.02), CA199 > 37 (P = 0.003)

210 was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (

211 nificant PCs included PC 4, correlating with lymph node metastasis (P = 0.04), and PC 10, with tumor

212 depth of invasion (P = 0.0120), presence of lymph node metastasis (P = 0.05), and survival (P = 0.01

213 ation were significantly less likely to show lymph node metastasis (P<0.001).

214 hat expression correlated significantly with lymph node metastasis (P=0.032), suggesting a disease-pr

215 station of a high-grade primary tumor and/or lymph node metastasis, precluding timely management of t

216 , 1.03-9.68] and a higher pathological tumor-lymph node-metastasis (pTNM) stage (OR, 3.11; 95% CI, 1.

217 , a similar rate of adverse histology, and a lymph node metastasis rate of 18%.

218 h aggressive features that include increased lymph node metastasis, reduced responsiveness to neoadju

219 relation of 11q22.1-q22.2 amplification with lymph node metastasis, reduced survival, and increased c

220 2%), which was significantly associated with lymph node metastasis (regional, P = 0.042; distant, P =

221 ocesses that underpin lymphatic invasion and lymph node metastasis remain poorly understood.

222 bulk, higher-grade primary cancer or from a lymph node metastasis resected at prostatectomy.

223 isease recurrence, advanced tumor stage, and lymph node metastasis, resulting in a 3.6-fold reduction

224 in paired clinical breast cancer primary and lymph-node metastasis samples, and that its expression s

225 endothelial growth factor-C (VEGF-C) to the lymph node metastasis seen in human prostate cancer.

226 ction (CLND) in patients without evidence of lymph node metastasis should be performed in patients wi

227 tes that clinical testing to assess risk for lymph node metastasis should be possible.

228 difference between pulmonary metastasis and lymph node metastasis showing that the androgen receptor

229 sociated with tumor size, depth of invasion, lymph node metastasis status and serum levels of carcino

230 tor receptor 2, clinical stage, and regional lymph node metastasis status.

231 < or = 1.0 cm were unlikely to have regional lymph node metastasis, suggesting that regional nodal ev

232 was observed in primary tumors with axillary lymph node metastasis than in node-negative tumors (n =

233 For example, in patients with lymph node metastasis, the deaths per 1000 person-years

234 atients with TNBC, once there is evidence of lymph node metastasis, the prognosis may not be affected

235 One of the carcinomas was a lymph node metastasis; the other 98 were primary carcino

236 tumor suppressor gene E-cadherin targets in lymph node metastasis through GSEA analyses.

237 On follow-up, 1 patient developed cervical lymph node metastasis, thus giving a false-negative rate

238 nfiltrating ductal breast adenocarcinoma and lymph node metastasis tissues taken at surgery.

239 Together with lymph node metastasis, tumor size, and histological grad

240 A total of 1.6% of patients with no lymph node metastasis underwent AI, 8.9% of those with o

241 node metastasis incidence (13%), spontaneous lymph node metastasis volume (46%), and experimental lun

242 6%) patients with BRAF mutation, concomitant lymph node metastasis was detected.

243 High maximal FAL of lymph node metastasis was significantly correlated with

244 Proportion of lymph node metastasis was significantly higher in study

245 The maximal FAL of lymph node metastasis was significantly lower than that

246 Lymph node metastasis was successfully imaged in animals

247 dscapes with those of the primary tumors and lymph node metastasis, we establish that 53% of the sing

248 lar extension, seminal vesicle invasion, and lymph node metastasis were scored retrospectively from 1

249 nd neck squamous cell carcinoma (HNSCC) with lymph node metastasis, where it also predicts poor progn

250 Of the 804 patients, 333 (41.4%) had no lymph node metastasis, whereas 471 (58.6%) had lymph nod

251 produced rapidly growing tumors and regional lymph node metastasis, whereas PC-3M-IkappaBalphaM cells

252 down-regulated in human breast cancer during lymph node metastasis, which has a significant negative

253 , especially in tissue post chemotherapy and lymph node metastasis, which is correlated with CSCs mar

254 e in vivo, pure genistein promoted increased lymph node metastasis, which was not observed with a soy

255 del, significantly reducing the incidence of lymph node metastasis while eliminating lung metastasis.

256 ermitted the diagnosis of necrotic or cystic lymph node metastasis without application of intravenous

257 On multivariable analysis, residual lymph node metastasis (ypN+) and TRG were the only indep